Cognitive impairment in remitted late-life depression is not associated with Alzheimer's disease-related CSF biomarkers

Loureiro, Júlia Cunha; Stella, Florindo; Pais, Marcos Vasconcelos; Radanovic, Márcia; Canineu, Paulo Renato; Joaquim, Helena Passarelli Giroud; Talib, Leda Leme; Forlenza, Orestes Vicente

doi:10.1016/j.jad.2020.03.166

Cited by 11 publications

(9 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Samples were divided into a lower fourth quintile of p‐tau concentration group or another group, as previously reported 17 . This resulted in a p‐tau cut‐off value of >38.2 pg./mL, which is similar to the results of previous studies 6,40,41 . In general, a higher level of p‐tau indicates neuronal degeneration 13 …”

Section: Methodssupporting

confidence: 65%

“…Alzheimer's disease (AD) dementia is characterised by impaired cognition accompanied by neuropsychiatric symptoms (NPS) related to mood such as depression, anxiety, and apathy 1–4 . These NPS related to mood symptoms (hereafter we refer to as NPS) are prodromal features of AD and mild cognitive impairment (MCI) 5–7 . Although early NPS was traditionally associated with frontotemporal dementia, there is growing evidence that NPS (recently termed mild behavioural impairment in MCI patients) may be related to AD progression 8,9 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients

Ozaki,

Hashimoto,

Udo

et al. 2023

Psychogeriatrics

View full text Add to dashboard Cite

BackgroundAlzheimer's disease (AD) dementia and mild cognitive impairment are characterised by impaired cognition accompanied by neuropsychiatric symptoms (NPS) relating to mood, including depression, anxiety, and apathy. However, the utility of AD biomarkers for predicting mood symptoms of NPS remains controversial. Herein, we analyzed the relationship between phosphorylated tau (p‐tau) and depression, anxiety, and apathy of NPS. We also examined the influence of genetic factors such as apolipoprotein E (APOE) ε4 on these relationships.MethodsWe conducted a cross‐sectional survey in older patients (n = 122) with normal cognition (n = 12), mild cognitive impairment (n = 46), and AD (n = 64) strictly diagnosed by the board of psychiatrists and neurologists of Hokkaido University. NPS of the patients were assessed using the Neuropsychiatric Inventory Questionnaire (NPI). All patients also received a lumbar puncture to obtain cerebral spinal fluid for assessment of p‐tau. The inverse probability weighting method was used to adjust for demographic differences between the p‐tau present group and the p‐tau absent group.ResultsThere was an association between p‐tau accumulation and decreased incidence of depression and apathy. APOE ε4 non‐carriers also showed a trend toward a negative association between p‐tau and depression, which was not evident in APOE ε4 carriers.ConclusionsWe provide new evidence for a negative correlation between p‐tau and depression and apathy of NPS, which may be influenced by APOE ε4. Future longitudinal studies are required to confirm the utility of p‐tau for predicting the course of mood symptoms in patients with cognitive decline.

show abstract

Section: Methodssupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients

Ozaki,

Hashimoto,

Udo

et al. 2023

Psychogeriatrics

View full text Add to dashboard Cite

show abstract

“…Los problemas de memoria reportados por las personas pueden tomarse como síntoma temprano de demencia, al igual que en los estudios de Cheng y Xiao (2014); sobre todo cuando estos son corroborados por familiares o cercanos. Las alteraciones en memoria son consecuencia de perturbaciones cerebrales como atrofia del hipocampo, el precuneus y el giro cingulado, estructuras estrechamente relacionadas con el sistema límbico y los procesos mnésicos (Loureiro et al, 2020), la memoria de trabajo, la flexibilidad cognitiva son los procesos mentales más afectados por el envejecimiento y pueden marcar la diferencia entre el envejecimiento normal y patologico.…”

Section: Discussionunclassified

Modelo de predicción de la demencia en adultos mayores de 60 años

Ortega

Charry

Prieto

et al. 2022

PSICO

View full text Add to dashboard Cite

Con el objetivo de determinar el aporte de las variables sociodemográficas, psicosociales y de salud, a un modelo de predicción de la demencia en población adulta mayor, se realizó un análisis secundario con los datos del estudio de “Salud, Bienestar y Envejecimiento. Bogotá, 2012”, con 2000 hombres y mujeres mayores de 60 años de áreas urbanas y rurales de Bogotá. Para seleccionar la muestra, se realizó un muestreo probabilístico, polietápico, de conglomerados y estratificado, basado en el censo nacional del 2005. Se utilizó el cuestionario SABE adaptado para Colombia. De acuerdo al nivel de medición de cada variable y la distribución de los datos, se realizaron análisis univariados y bivariados, con la demencia como variable criterio y como predictoras las variables sociodemográficas, de salud; se incluyeron 30 variables. Se encontró que el 40.1% de la varianza de la demencia es explicada por la edad, nivel educativo y socioeconómico, hipertensión, accidente cerebrovascular, depresión, disfuncionalidad motora, fractura de cadera, salud comparada, víctima de atraco, consumo de alcohol, memoria, autorreporte de memoria y memoria comparada. Los hallazgos ofrecen un modelo estadístico que permite la detección de los factores de riesgo para la demencia y el análisis de los potencialmente modificables para su prevención.

show abstract

“…154 Still, although elderly subjects whose dominant symptom is a change in behavior constitute an attractive target for ruling out AD pathology with biomarkers, there is no strong evidence in the literature supporting this indication. [155][156][157][158] Recently, CSF neurofilament light chain (NfL) has emerged as a promising biomarker to differentiate frontotemporal dementia from psychiatric conditions 155,[159][160][161] and plasma NfL as a marker of mild behavioral impairment 162 ; however, further studies are necessary to support the clinical utility of this biomarker.…”

Section: Tamentioning

confidence: 99%

CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

Brisson

Brodeur

Létourneau-Guillon

et al. 2020

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTDs) have provided evidence-based dementia diagnostic and treatment guidelines for Canadian clinicians and researchers. We present the results from the Neuroimaging and Fluid Biomarkers Group of the 5th CCCDTD (CCCDTD5), which addressed topics chosen by the steering committee to reflect advances in the field and build on our previous guidelines. Recommendations on Imaging and Fluid Biomarker Use from this Conference cover a series of different fields. Prior structural imaging recommendations for both computerized tomography (CT) and magnetic resonance imaging (MRI) remain largely unchanged, but MRI is now more central to the evaluation than before, with suggested sequences described here. The use of visual rating scales for both atrophy and white matter anomalies is now included in our recommendations. Molecular imaging with [ 18 F]-fluorodeoxyglucose ([18F]-FDG) Positron Emisson Tomography (PET) or [ 99m Tc]hexamethylpropyleneamine oxime/ethylene cysteinate dimer ([ 99m Tc]-HMPAO/ECD) Single Photon Emission Tomography (SPECT), should now decidedly favor PET. The value of [ 18 F]-FDG PET in the assessment of neurodegenerative conditions has been established with greater certainty since the previous conference, and it has now been recognized as a useful biomarker to establish the presence of neurodegeneration by a number of professional organizations around the world. Furthermore, the role of amyloid PET has been clarified and our recommendations follow those from other groups in multiple countries. SPECT with [ 123 I]-ioflupane (DaTscan TM ) is now included as a useful study in differentiating Alzheimer's disease (AD) from Lewy body disease. Finally, liquid biomarkers are in a rapid phase of development and, could lead to a revolution in the assessment AD and other neurodegenerative conditions at a reasonable cost.We hope these guidelines will be useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to the use of neuroimaging and liquid biomarkers in clinical dementia evaluation and management.

show abstract

Cognitive impairment in remitted late-life depression is not associated with Alzheimer's disease-related CSF biomarkers

Cited by 11 publications

References 54 publications

Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients

Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients

Modelo de predicción de la demencia en adultos mayores de 60 años

CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

Contact Info

Product

Resources

About